Kasuga Yoshifumi, Takahashi Marina, Kajikawa Kaoru, Akita Keisuke, Tamai Junko, Fukuma Yuka, Tanaka Yuya, Hasegawa Keita, Otani Toshimitsu, Ikenoue Satoru, Tanaka Mamoru
Department of Obstetrics and Gynecology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
J Diabetes Investig. 2024 Dec;15(12):1803-1808. doi: 10.1111/jdi.14318. Epub 2024 Sep 19.
AIMS/INTRODUCTION: This study evaluated the risk factors for insulin therapy before 24 gestational weeks (early insulin therapy) in pregnant women with gestational diabetes diagnosed before 24 gestational weeks (E-GDM).
This study included 530 singleton mothers with E-GDM who underwent a 75 g oral glucose tolerance test (OGTT) in the first trimester at Keio University Hospital between January 2013 and December 2021. E-GDM can be classified according to its management into only diet therapy until delivery (Diet E-GDM), insulin therapy started before 24 gestational weeks (EarlyIns E-GDM), and insulin therapy started after 24 gestational weeks (LateIns E-GDM). We analyzed the risk factors for EarlyIns E-GDM.
Patients with EarlyIns E-GDM had a significantly higher maternal age at delivery, pre-pregnancy BMI, first trimester hemoglobin A1c, 1 h plasma glucose levels (1 h-PG), and 2 h-PG, as well as a more pronounced initial increase and subsequent decrease, compared with those in the Diet E-GDM group. However, the Apgar scores at both 1 and 5 min were significantly lower in patients with EarlyIns E-GDM than in those with Diet E-GDM. The number of abnormal values in the OGTT showed the largest area under the receiver operating characteristic curve (AUC) for predicting EarlyIns E-GDM (0.83, 95% confidence interval [CI]: 0.79-0.86), followed by the 1 h-PG value (AUC: 0.81, 95% CI: 0.77-0.85). The initial increase showed the third largest AUC (0.78, 95% CI: 0.74-0.82).
Although further research is needed, our data suggest the importance of early insulin therapy in cases of E-GDM with multiple abnormal OGTT values, especially with high 1 h-PG levels and initial increase.
目的/引言:本研究评估了孕24周前诊断为妊娠期糖尿病(早发型妊娠期糖尿病,E-GDM)的孕妇在孕24周前接受胰岛素治疗(早期胰岛素治疗)的危险因素。
本研究纳入了530名单胎妊娠且患有E-GDM的母亲,她们于2013年1月至2021年12月在庆应义塾大学医院孕早期接受了75克口服葡萄糖耐量试验(OGTT)。E-GDM根据其管理方式可分为仅饮食治疗至分娩(饮食治疗型E-GDM)、孕24周前开始胰岛素治疗(早发型胰岛素治疗型E-GDM)和孕24周后开始胰岛素治疗(晚发型胰岛素治疗型E-GDM)。我们分析了早发型胰岛素治疗型E-GDM的危险因素。
与饮食治疗型E-GDM组相比,早发型胰岛素治疗型E-GDM患者的分娩时母亲年龄、孕前体重指数、孕早期糖化血红蛋白A1c、1小时血浆葡萄糖水平(1 h-PG)和2小时血浆葡萄糖水平显著更高,且初始升高和随后下降更为明显。然而,早发型胰岛素治疗型E-GDM患者1分钟和5分钟时的阿氏评分显著低于饮食治疗型E-GDM患者。OGTT中异常值的数量在预测早发型胰岛素治疗型E-GDM方面显示出最大的受试者工作特征曲线下面积(AUC)(0.83,95%置信区间[CI]:0.79 - 0.86),其次是1 h-PG值(AUC:0.81,95% CI:0.77 - 0.85)。初始升高显示出第三大的AUC(0.78,95% CI:0.74 - 0.82)。
尽管需要进一步研究,但我们的数据表明,在具有多个OGTT异常值的E-GDM病例中,尤其是1 h-PG水平高和有初始升高的情况下,早期胰岛素治疗具有重要意义。